Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

ECHELON-2 Study Group

Research output: Contribution to journalArticlepeer-review

238 Scopus citations

Fingerprint

Dive into the research topics of 'Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences